 Zacks Investment Research downgraded shares of Eidos Therapeutics NASDAQ:EIDX from a buy rating to a hold rating in a research report released on Monday morning, Zacks.com reports. According to Zacks, Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. ... 